COCP Rasio cepet Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. (COCP) develops specialized antiviral agents leveraging proprietary crystallography technology and a debt-free balance sheet. Market fluctuations in COCP shares, where the indicator stands at 1.28, confirm this status. Growth is driven by the development of oral medications for COVID-19 and influenza. Meanwhile, the company's R&D capacities are fully utilized, and equipment is functioning without disruption.

For Cocrystal Pharma, Inc. (COCP), which focuses on R&D for antiviral treatments, maintaining access to liquid assets excluding illiquid inventories is critical. By analyzing the acid-test ratio, an investor assesses the company's ability to cover short-term liabilities using only cash and accounts receivable, which confirms financial stability during the preparation of scientific data for regulators and minimizes the risk of cash flow gaps.